---

---

tags : Phase 2    crawled time : 16:00   

save search

---

Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
Published: 2023-08-21 (Crawled : 16:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K |

Transportation and Warehousing

| 88138.99% | O: -6.29% H: 17.45% C: -9.4%
antibody phase 2

---

Phase 2 of the Farmington Canal Heritage Trail in Plainville – CT.gov
Published: 2023-07-05 (Crawled : 16:00) - spacfeed.com
ARVL | News | $0.49 0.37% 2.5M |

Manufacturing

| -80.0% | O: -6.18% H: 0.0% C: 0.0%
phase 2

---

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Published: 2023-05-02 (Crawled : 16:00) - biospace.com/
HZNP | $116.3 0.03% 29M |

Health Technology

| 3.89% | O: 0.04% H: 0.04% C: -0.21%
lupus treatment trial therapeutics phase 2

---

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19
Published: 2023-04-03 (Crawled : 16:00) - biospace.com/
PRDS | $2.16 1.37% 2.4M |

Professional, Scientific, and T...

| 62.12% | O: -11.36% H: 28.21% C: 22.22%
covid-19 treatment trial results phase 2

---

Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
SKYE | $12.845 -8.45% -9.23% 110K |

Transportation and Warehousing

| 36821.05% | O: 2.11% H: 36.6% C: 29.64%
sbi-100 pharma services trial bioscience phase 2 ophthalmic emulsion

---

Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug
Published: 2022-09-16 (Crawled : 16:00) - biospace.com/
BIIB | $201.91 4.52% 4.32% 3.3M |

Health Technology

| -6.55% | O: -0.09% H: 1.28% C: 0.83%
drug lupus trial promise phase 2

---

Lion One Announces New High-Grade, Near Surface Gold in Drill Results from Phase 2 Infill Program at Tuvatu
Published: 2022-09-08 (Crawled : 16:00) - liononemetals.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| 13.41% | O: 2.54% H: 1.88% C: 1.88%
program one results phase 2

---

Clene Reports Positive Topline Results for CNM-Au8® in the Phase 2 VISIONARY-MS Trial in Multiple Sclerosis
Published: 2022-08-15 (Crawled : 16:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K |

| -90.14% | O: -4.35% H: 13.03% C: 10.61%
au8 topline trial positive sclerosis phase 2 cnm-au8 multiple sclerosis

---

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer
Published: 2022-08-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 142.62% | O: -1.18% H: 1.46% C: 0.05%
ALXO M | $16.24 4.77% 4.56% 440K |

Commercial Services

| 21.19% | O: 2.97% H: 6.15% C: -1.44%
trial cancer phase 2

---

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data
Published: 2022-07-26 (Crawled : 16:00) - biospace.com/
SNPX | $4.6 0.66% 0.65% 14K |

Professional, Scientific, and T...

| -10.31% | O: 2.05% H: 8.08% C: 4.23%
phase 2

---

Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
Published: 2022-06-21 (Crawled : 16:00) - biospace.com/
CLDX | $36.975 -2.11% -2.15% 390K |

Health Technology

| 62.38% | O: 3.63% H: 0.0% C: 0.0%
urticaria phase 2

---

AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| 143.88% | O: 3.83% H: 0.0% C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M |

Health Technology

| -30.72% | O: 0.01% H: 0.0% C: 0.0%
therapeutics asco phase 2

---

Sagimet Biosciences to Present Additional Biomarker Phase 2 Data on Denifanstat (TVB-2640) in NASH Patients at DDW 2022
Published: 2022-05-04 (Crawled : 16:00) - biospace.com/
SGMT | News | $4.15 -3.04% -3.13% 220K |

Health Technology

| Email alert Add to watchlist
tvb-2640 nash biomarkers phase 2

---

AEON Biopharma Completes Enrollment in Phase 2 Clinical Study of ABP-450 in Cervical DystoniaTopline data expected to be announced in the second half of 2022
Published: 2022-04-11 (Crawled : 16:00) - biospace.com/
AEON | $4.01 -6.74% 0.5% 40K |

| Email alert Add to watchlist
abp-450 biopharma enroll phase 2

---

Evergold Advances High-Grade Rockland Nevada Gold-Silver Property; Anticipates Permit for Phase 1 Drill Program Mid-Year
Published: 2022-03-08 (Crawled : 16:00) - globenewswire.com
NEM | News | $38.6 2.36% -0.26% 11M |

Non-Energy Minerals

| -49.27% | O: 4.94% H: 3.53% C: -0.5%
program phase 1 phase 2

---

Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF and Chronic Cough Trial
Published: 2021-12-02 (Crawled : 16:00) - biospace.com/
AGNPF | $0.089 178.69% 75K |

Health Technology

| -97.5% | O: -0.28% H: 0.14% C: -5.57%
phase 2 trial chronic cough enroll

---

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative Symptoms of Schizophrenia
Published: 2021-09-30 (Crawled : 16:00) - globenewswire.com
NERV | $2.53 0.0% 3.9K |

Health Technology

| 42.94% | O: 2.82% H: 3.3% C: -4.4%
treatment phase 2 schizophrenia results phase 2b phase 3 roluperidone

---

Sorrento Announces Enrollment of First Subject in Brazil Phase 2 Study of COVI-MSC for Treatment of COVID-19 Associated Acute Respiratory Distress in ICU Patients
Published: 2021-09-02 (Crawled : 16:00) - globenewswire.com
SRNE | $0.015 -8.85% 56K |

Health Technology

| -99.89% | O: 0.22% H: 1.42% C: -0.11%
covid treatment phase 2 brazil respiratory enroll

---

Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients
Published: 2021-08-27 (Crawled : 16:00) - globenewswire.com
SAVA M | $20.75 0.97% 0.96% 480K |

Health Technology

| -71.0% | O: -27.68% H: 27.03% C: 13.86%
alzheimer phase 2 phase 2b alzheimer’s alzheimer's

---

NIH Advances ACTIV-5/BET-B Trial Evaluating Lenzilumab from a Phase 2 Exploratory Study to a Phase 2/3 Study for the Treatment of COVID-19
Published: 2021-07-30 (Crawled : 16:00) - biospace.com/
HGEN | $0.0361 -61.5% 120M |

Health Technology

| -99.78% | O: -1.39% H: 0.0% C: 0.0%
covid treatment phase 2 phase 2/3 lenzilumab trial

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---